Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00631553

Enrollment

Registered

2008-03-07

Start date

2006-06-30

Completion date

2009-12-31

Last updated

2008-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney

Brief summary

The purpose of this study is to determine if contrast enhanced ultrasound (CEU) using microbubbles, is useful in assessing changes in kidney blood flow.

Interventions

DRUGperflutren lipid microspheres

1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy adults * Males and females * Ages 18-65 years old

Exclusion criteria

* Pregnancy or lactation * H/o kidney disease * H/o congestive heart failure, ischemic heart disease, severe pulmonary disease or allergy to the drug * H/o any cardiovascular disease * Abnormal liver function (liver function tests out of specified ranges) * Screening urinalysis which indicates infection or inflammation * Taking regular medications (except for over-the-counter vitamins or hormonal contraceptives.) * Taking supplements, like protein shakes * Unwilling or unable to eat chicken (used as protein meal)

Countries

United States

Contacts

Primary ContactKambiz Kalantarinia, MD

kk6c@virginia.edu434 924 5125

Backup ContactLori Ratliff, RN ANP

lbr@virginia.edu434 924 5820

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026